CVS Pharmacy to Pay $315M to Settle Opioid Prescription Claims
CVS sits 26% above its 52-week low of $69.51 on light trading volume (0.4× avg).
Summary
CVS Pharmacy agreed to pay $315 million to resolve federal allegations that it illegally filled opioid prescriptions and submitted false Medicare claims. The settlement includes a memorandum of agreement with the DEA requiring a hotline for reporting suspected illegal dispensing. This is a material legal liability for CVS, though the amount is modest relative to its $112 billion market cap. The news follows a strong Q2 and ongoing Medicare Advantage restructuring, adding a new regulatory overhang. No specific upcoming event is named.
At the time of this announcement, CVS was trading at $87.51 on NYSE in the Trade & Services sector, with a market capitalization of approximately $111.9B. The 52-week trading range was $69.51 to $110.68. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.